PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
Authors
Keywords
-
Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 17, Issue 12, Pages 1097-1108
Publisher
Informa UK Limited
Online
2017-10-26
DOI
10.1080/14737159.2017.1398083
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society
- (2018) Erik Thunnissen et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?
- (2018) Meng Qiao et al. Clinical Lung Cancer
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas
- (2017) Sehui Kim et al. EUROPEAN JOURNAL OF CANCER
- Aligning digital CD8+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma
- (2017) Esther Conde et al. HISTOPATHOLOGY
- Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
- (2017) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
- (2017) Antonio Marchetti et al. Journal of Thoracic Oncology
- Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress
- (2017) Lina Abdul Karim et al. Journal of Thoracic Oncology
- Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer
- (2017) Chao Li et al. Journal of Thoracic Oncology
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
- (2017) Hironori Uruga et al. Journal of Thoracic Oncology
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Prognostic significance of PD-L1 in solid tumor
- (2017) Qianqian Wang et al. MEDICINE
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
- (2017) Takahiro Tsujikawa et al. Cell Reports
- Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
- (2017) Birgit G. Skov et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what’s next?
- (2017) Marius Ilie et al. Journal of Thoracic Disease
- Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration
- (2017) Alessandro Tuzi et al. Journal of Thoracic Disease
- An update on the role of advanced diagnostic bronchoscopy in the evaluation and staging of lung cancer
- (2017) Adam R. Belanger et al. Therapeutic Advances in Respiratory Disease
- Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy
- (2017) Hélène Roussel et al. OncoImmunology
- Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
- (2017) Ilija Nenadić et al. Cancers
- Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis
- (2017) Tiancheng Zhao et al. PLoS One
- Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
- (2017) Marius Ilie et al. PLoS One
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- Non–Small Cell Lung Cancer, PD-L1, and the Pathologist
- (2016) Keith M. Kerr et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
- (2016) Marisa Dolled-Filhart et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue
- (2016) Marisa Dolled-Filhart et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
- (2016) Keith M. Kerr et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
- (2016) Alain C. Borczuk et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations
- (2016) Fang Zhou et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics
- (2016) Harald Enzmann et al. Biomarkers in Medicine
- Enjeux et limites actuelles de l’évaluation du statut de PD-L1 par immunohistochimie sur des biopsies bronchiques
- (2016) Véronique Hofman et al. BULLETIN DU CANCER
- Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
- (2016) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy
- (2016) AS Mansfield et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
- (2016) Jacquelyn Smith et al. Diagnostic Pathology
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- (2016) Marlon C. Rebelatto et al. Diagnostic Pathology
- PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation
- (2016) Ian A Cree et al. HISTOPATHOLOGY
- The (Con-) Fusion in ALK Diagnostics: When Food and Drug Administration–Approved Algorithms Fail
- (2016) Jessica Jürgens et al. JOURNAL OF CLINICAL ONCOLOGY
- A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform
- (2016) Tzahi Neuman et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome
- (2016) Marius Ilie et al. MODERN PATHOLOGY
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- (2016) Andreas H Scheel et al. MODERN PATHOLOGY
- An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
- (2016) John Cogswell et al. Molecular Diagnosis & Therapy
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
- (2016) Marius Ilie et al. VIRCHOWS ARCHIV
- Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
- (2016) Charlotte Roach et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy
- (2016) David J. Pinato et al. OncoImmunology
- PD-L1 Expression as a Predictive Biomarker
- (2016) Feriyl Bhaijee et al. JAMA Oncology
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
- (2016) Mari Mino-Kenudson et al. Cancer Biology & Medicine
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer
- (2015) Philip T. Cagle et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Complementary versus companion diagnostics: apples and oranges?
- (2015) Christopher-Paul Milne et al. Biomarkers in Medicine
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
- (2015) A. S. Mansfield et al. CLINICAL CANCER RESEARCH
- Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
- (2015) Jan Trøst Jørgensen EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics
- (2015) Kelly Elliott et al. JOURNAL OF CLINICAL PATHOLOGY
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- Sense and nonsense in the process of accreditation of a pathology laboratory
- (2015) Elodie Long-Mira et al. VIRCHOWS ARCHIV
- Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
- (2015) Alberto Ocana et al. Oncotarget
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis
- (2015) Pin Wu et al. PLoS One
- Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
- (2014) H. Koeppen et al. CLINICAL CANCER RESEARCH
- "Companion Diagnostics": Has Their Time Come and Gone?
- (2014) F. R. Hirsch et al. CLINICAL CANCER RESEARCH
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects
- (2014) Dana Olsen et al. Frontiers in Oncology
- L’accréditation selon la norme ISO 15189 d’un laboratoire de pathologie et de génétique somatique (LPCE, CHU de Nice) : retour d’expérience
- (2013) Kevin Washetine et al. ANNALES DE PATHOLOGIE
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Do companion diagnostics make economic sense for drug developers?
- (2012) Amit Agarwal New Biotechnology
- External quality control for immunocytochemistry on cytology samples: a review of UK NEQAS ICC (cytology module) results
- (2011) I. S. Kirbis et al. CYTOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation